{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:09:56Z","timestamp":1789042196783,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.08.013","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T07:05:28Z","timestamp":1787123128000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of 8 Gy TBI-Busulfan-Fludarabine Conditioning With Post-Transplant Cyclophosphamide for Pediatric High-Risk or Relapsed Acute Lymphoblastic Leukemia"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-1691","authenticated-orcid":false,"given":"Jae Won","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suejung","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongkoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0735-0287","authenticated-orcid":false,"given":"Jae Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4855-390X","authenticated-orcid":false,"given":"Nack-Gyun","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.08.013_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.782785","article-title":"Allogeneic hematopoietic stem cell transplantation for children with acute lymphoblastic leukemia: shifting indications in the era of immunotherapy","volume":"9","author":"Truong","year":"2021","journal-title":"Front Pediatr"},{"issue":"17","key":"10.1016\/j.jtct.2026.08.013_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10173790","article-title":"The role of allogeneic hematopoietic stem cell transplantation in pediatric leukemia","volume":"10","author":"Algeri","year":"2021","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.013_bib0003","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.2014.58.9747","article-title":"Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-the ALL-SCT-BFM-2003 trial","volume":"33","author":"Peters","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.013_bib0004","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","article-title":"Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion","volume":"130","author":"Locatelli","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.013_bib0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood all: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.013_bib0006","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000812","article-title":"Reduced 8-gray compared to standard 12-gray total body irradiation for allogeneic transplantation in first remission acute lymphoblastic leukemia: a study of the acute leukemia working party of the EBMT","volume":"7","author":"Spyridonidis","year":"2023","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.013_bib0007","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41409-025-02762-4","article-title":"Reduced intensity conditioning with 8 Gy total body irradiation in adult patients with acute lymphoblastic leukemia","volume":"61","author":"Wethmar","year":"2026","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.013_bib0008","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.013_bib0009","doi-asserted-by":"crossref","first-page":"424.e1","DOI":"10.1016\/j.jtct.2021.01.016","article-title":"Outcomes of unmanipulated haploidentical transplantation using post-transplant cyclophosphamide (PT-Cy) in pediatric patients with acute lymphoblastic leukemia","volume":"27","author":"Ruggeri","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"18","key":"10.1016\/j.jtct.2026.08.013_bib0010","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1182\/bloodadvances.2023010281","article-title":"Prospective PTCTC trial of myeloablative haplo-BMT with posttransplant cyclophosphamide for pediatric acute leukemias","volume":"7","author":"Fierro-Pineda","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.013_bib0011","doi-asserted-by":"crossref","first-page":"158.e1","DOI":"10.1016\/j.jtct.2021.11.009","article-title":"Outcome of haploidentical peripheral blood allografts using post-transplantation cyclophosphamide compared to matched sibling and unrelated donor bone marrow allografts in pediatric patients with hematologic malignancies: a single-center analysis","volume":"28","author":"Srinivasan","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"25","key":"10.1016\/j.jtct.2026.08.013_bib0012","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.013_bib0013","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbmt.2014.09.029","article-title":"A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia","volume":"21","author":"Yahng","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.013_bib0014","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2008.17.6065","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.013_bib0015","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.013_bib0016","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.013_bib0017","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41409-020-0854-0","article-title":"Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-a multicenter EBMT-PDWP study","volume":"55","author":"Willasch","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.013_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70026","article-title":"Long-term outcomes of reduced-toxicity conditioning using 8-gray total body irradiation, fludarabine, and cyclophosphamide in children, adolescents, and young adults with hematological malignancies","volume":"43","author":"Morokawa","year":"2025","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.013_bib0019","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/bbmt.2001.v7.pm11669214","volume":"7","author":"Antin","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2026.08.013_bib0020","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.013_bib0021","first-page":"122","article-title":"Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial","volume":"111","author":"Balduzzi","year":"2026","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.08.013_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.777108","article-title":"Minimal residual disease prior to and after haematopoietic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia: what level of negativity is relevant?","volume":"9","author":"Merli","year":"2021","journal-title":"Front Pediatr"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.013_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28079","article-title":"The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"67","author":"Friend","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2026.08.013_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100966","article-title":"Could (should) we abandon total body irradiation for conditioning in children with leukemia","volume":"56","author":"Handgretinger","year":"2022","journal-title":"Blood Rev"},{"issue":"26","key":"10.1016\/j.jtct.2026.08.013_bib0025","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.013_bib0026","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/cncr.31228","article-title":"Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplant cyclophosphamide","volume":"124","author":"Ruggeri","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.08.013_bib0027","volume":"11","author":"Moreno","year":"2023","journal-title":"Front Pediatr"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.013_bib0028","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/bloodadvances.2018027003","article-title":"The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia","volume":"3","author":"Yeshurun","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.08.013_bib0029","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-026-02797-1","article-title":"Impact of acute GvHD severity on survival and disease relapse in pediatric patients undergoing allogeneic stem cell transplantation for acute lymphoblastic leukemia: an analysis based on the EBMT-PDWP registry","author":"Szmit","year":"2026","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.013_bib0030","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jtct.2022.01.013","article-title":"Association between the magnitude of intravenous busulfan exposure and development of hepatic Veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation","volume":"28","author":"Bognar","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.013_bib0031","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41409-025-02793-x","article-title":"Defibrotide for prophylaxis of sinusoidal obstruction syndrome\/veno-occlusive disease (SOS\/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"61","author":"Corbacioglu","year":"2026","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.013_bib0032","article-title":"Refining busulfan exposure enhances pediatric ALL HSCT outcomes: insights from the international FORUM study","author":"Ben Hassine","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.013_bib0033","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14364","article-title":"Evaluation of the risk factors for BK virus-associated hemorrhagic cystitis in pediatric bone marrow transplantation patients: does post-transplantation cyclophosphamide increase the frequency?","volume":"27","author":"Ersoy","year":"2023","journal-title":"Pediatr Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.013_bib0034","doi-asserted-by":"crossref","first-page":"182.e1","DOI":"10.1016\/j.jtct.2024.12.006","article-title":"Incidence, risk factors, and outcomes of bk hemorrhagic cystitis in hematopoietic stem cell transplantation from hla-matched and haploidentical donors with post-transplant cyclophosphamide","volume":"31","author":"Chorao","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.013_bib0035","article-title":"Long-term follow-up after adoptive transfer of BK-virus-specific T cells in hematopoietic stem cell transplant recipients","volume":"11","author":"Koldehoff","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.013_bib0036","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.013_bib0037","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1038\/s41375-022-01693-z","article-title":"Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial","volume":"36","author":"Eichinger","year":"2022","journal-title":"Leukemia"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:22:22Z","timestamp":1789039342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":37,"alternative-id":["S2666636726006160"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.013","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of 8 Gy TBI-Busulfan-Fludarabine Conditioning With Post-Transplant Cyclophosphamide for Pediatric High-Risk or Relapsed Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}